See the DrugPatentWatch profile for Alunbrig
What is Alunbrig (aluminum brigatinib) used for?
Alunbrig is the brand name for brigatinib, a cancer medicine used to treat certain people with non-small cell lung cancer (NSCLC) that has a specific genetic change (an ALK rearrangement). It is used when the disease is ALK-positive and may be used in different lines of therapy depending on the patient’s situation and prior treatment history.
What does “Alunbrig ema” likely refer to?
“EMA” usually means the European Medicines Agency. If you’re asking about Alunbrig’s EMA status, you would typically be looking for one of these EMA items:
- the European authorization/approval (marketing authorization)
- the EMA product information (summary of product characteristics, or SmPC)
- EMA safety updates (pharmacovigilance signals, periodic safety reporting, restrictions)
Has Alunbrig been approved by the EMA?
Alunbrig is an EMA-regulated product, but the exact approval details depend on which indication and time period you mean (initial ALK-positive NSCLC approval versus later label updates). To answer precisely, I’d need the exact wording you saw (for example, “Alunbrig EMA SmPC,” “Alunbrig EMA decision,” or the date/indication you’re interested in).
If you tell me your goal, I can pinpoint the right “EMA” document
Reply with one of these and I’ll narrow it down:
- the exact EMA link/title you’re looking at
- whether you want “SmPC” details, dosing/indication, or safety warnings
- the indication (e.g., first-line vs after crizotinib)
Sources: None provided.